4SC AG - Product Pipeline Review

Global Markets Direct’s, ‘4SC AG - Product Pipeline Review - 2016’, provides an overview of the 4SC AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by 4SC AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of 4SC AG

The report provides overview of 4SC AG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses 4SC AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features 4SC AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate 4SC AG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for 4SC AG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 4SC AG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

4SC AG Snapshot 5

4SC AG Overview 5

Key Information ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

4SC AG Snapshot 5

4SC AG Overview 5

Key Information 5

Key Facts 5

4SC AG - Research and Development Overview 6

Key Therapeutic Areas 6

4SC AG - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

4SC AG - Pipeline Products Glance 13

4SC AG - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

4SC AG - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

4SC AG - Drug Profiles 17

resminostat 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

vidofludimus 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

4SC-202 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

4SC-205 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecule for Malaria 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecules for Neurological Disorders 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules to Inhibit Bromodomain for Cancer 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

4SC AG - Pipeline Analysis 34

4SC AG - Pipeline Products by Target 34

4SC AG - Pipeline Products by Route of Administration 35

4SC AG - Pipeline Products by Molecule Type 36

4SC AG - Pipeline Products by Mechanism of Action 37

4SC AG - Recent Pipeline Updates 38

4SC AG - Dormant Projects 45

4SC AG - Discontinued Pipeline Products 46

Discontinued Pipeline Product Profiles 46

4SC-203 46

4SC-207 46

resminostat 46

4SC AG - Company Statement 47

4SC AG - Locations And Subsidiaries 49

Head Office 49

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

List of Tables

4SC AG, Key Information 5

4SC AG, Key Facts 5

4SC AG - Pipeline by Indication, 2016 7

4SC AG - Pipeline ...

List of Tables

4SC AG, Key Information 5

4SC AG, Key Facts 5

4SC AG - Pipeline by Indication, 2016 7

4SC AG - Pipeline by Stage of Development, 2016 9

4SC AG - Monotherapy Products in Pipeline, 2016 10

4SC AG - Partnered Products in Pipeline, 2016 11

4SC AG - Partnered Products/ Combination Treatment Modalities, 2016 12

4SC AG - Phase II, 2016 13

4SC AG - Phase I, 2016 14

4SC AG - Preclinical, 2016 15

4SC AG - Discovery, 2016 16

4SC AG - Pipeline by Target, 2016 34

4SC AG - Pipeline by Route of Administration, 2016 35

4SC AG - Pipeline by Molecule Type, 2016 36

4SC AG - Pipeline Products by Mechanism of Action, 2016 37

4SC AG - Recent Pipeline Updates, 2016 38

4SC AG - Dormant Developmental Projects,2016 45

4SC AG - Discontinued Pipeline Products, 2016 46

List of Figures

List of Figures

4SC AG - Pipeline by Top 10 Indication, 2016 7

4SC AG - Pipeline by Stage of Development, 2016 9

4SC AG ...

List of Figures

4SC AG - Pipeline by Top 10 Indication, 2016 7

4SC AG - Pipeline by Stage of Development, 2016 9

4SC AG - Monotherapy Products in Pipeline, 2016 10

4SC AG - Partnered Products in Pipeline, 2016 11

4SC AG - Pipeline by Target, 2016 34

4SC AG - Pipeline by Route of Administration, 2016 35

4SC AG - Pipeline by Molecule Type, 2016 36

4SC AG - Pipeline Products by Mechanism of Action, 2016 37

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports